Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AURORA phase II trial of atezolizumab in urinary tract squamous cell carcinoma
ISRCTN83474167Phase 2Completed
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in bladder squamous cell carcinoma, sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Best overall objective response rate. Started May 2022; status: completed.
02
Drugs
atezolizumab
03
Conditions
bladder squamous cell carcinoma
Beyond the preview
Go deeper on ISRCTN83474167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN83474167.